A focus on the use of subcutaneous C1-inhibitor for treatment of hereditary angioedema
- 6 April 2020
- journal article
- research article
- Published by Taylor & Francis Ltd in Expert Review of Clinical Immunology
- Vol. 16 (5), 451-455
- https://doi.org/10.1080/1744666x.2020.1750953
Abstract
Introduction: HAE is a very debilitating disease that causes significant distress for patients not only during an acute attack but also constant fear for a subsequent attack. It is important to address long-term prophylactic (LTP) therapy to prevent attacks, decrease morbidity and increase quality of life. When discussing LTP, the drug burden, convenience and efficacy must be taken into account. Areas covered: We review the literature and the different phases of clinical trials leading up to approval by the US FDA of subcutaneous highly concentrated C1-Inhibitor (SC-C1-INH), called Haegarda. The dose approved is of 60 IU/kg twice weekly showing significant improvement in reduction of attacks and need for on-demand therapy for attacks with minimal side effects. Expert opinion: SC-C1-INH has added significantly to the armamentarium of physicians that treat HAE. The ability to achieve a steady state of C1-INH above 40% function is key to the success of the drug. The drug burden is a SC injection twice a week that exceeds the newly approved lanadelumab. The benefit may be that the protein that is deficient in HAE is replaced and with this the complement, fibrinolytic, coagulation pathways and contact system are also regulated; however, evidence that this is of benefit is still lacking.Keywords
This publication has 16 references indexed in Scilit:
- Exposure-Response Model of Subcutaneous C1-Inhibitor Concentrate to Estimate the Risk of Attacks in Patients With Hereditary AngioedemaCPT: Pharmacometrics & Systems Pharmacology, 2018
- The international WAO/EAACI guideline for the management of hereditary angioedema – the 2017 revision and updateWorld Allergy Organization Journal, 2018
- Prevention of Hereditary Angioedema Attacks with a Subcutaneous C1 InhibitorThe New England Journal of Medicine, 2017
- Phase II study results of a replacement therapy for hereditary angioedema with subcutaneous C1‐inhibitor concentrateAllergy, 2015
- Pharmacokinetics of plasma‐derived C1‐esterase inhibitor after subcutaneous versus intravenous administration in subjects with mild or moderate hereditary angioedema: the PASSION studyTransfusion, 2013
- Nanofiltered C1-Esterase Inhibitor for the Acute Management and Prevention of Hereditary Angioedema Attacks due to C1-Inhibitor Deficiency in ChildrenThe Journal of Pediatrics, 2013
- Target levels of functional C1‐inhibitor in hereditary angioedemaAllergy, 2011
- 2010 International consensus algorithm for the diagnosis, therapy and management of hereditary angioedemaAllergy, Asthma & Clinical Immunology, 2010
- Hereditary AngioedemaThe New England Journal of Medicine, 2008
- Subcutaneous drug delivery and the role of the lymphaticsDrug Discovery Today: Technologies, 2005